Jushi Holdings (JUSHF) Cash from Investing Activities (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Cash from Investing Activities of -$3.9 million for Q2 2026, down 749.02% year-over-year from $600444.1 in Q2 2025, and up 4.49% quarter-over-quarter from -$4.1 million in Q1 2026.
Jushi Holdings (JUSHF) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Cash from Investing Activities for 6 consecutive years, with -$3.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 749.02% year-over-year to -$3.9 million; the TTM figure through Jun 2026 stood at -$16.4 million (down 27.26% YoY), while the FY2025 annual figure was -$13.2 million, down 87.09% from the prior year.
- Cash from Investing Activities improved to -$3.9 million in Q2 2026 per JUSHF's latest filing, from -$4.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.7 million in Q2 2024 and bottomed at -$38.1 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged -$6.4 million across 5 years, with a median of -$4.0 million in 2026.
- On a YoY basis, Cash from Investing Activities climbed as much as 348.1% in 2024 and fell as far as 2112.2% in 2024.
- Jushi Holdings' Cash from Investing Activities stood at -$7.7 million in 2022, then surged by 95.76% to -$328000.0 in 2023, then plunged by 2112.2% to -$7.3 million in 2024, then soared by 57.69% to -$3.1 million in 2025, then decreased by 26.94% to -$3.9 million in 2026.
- Business Quant data shows JUSHF's Cash from Investing Activities at -$3.9 million in Q2 2026, -$4.1 million in Q1 2026, and -$3.1 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.90 Mn |
| Jun 30, 2026 | -3.90 Mn |
| Mar 31, 2026 | -4.08 Mn |
| Mar 31, 2026 | -4.08 Mn |
| Dec 31, 2025 | -3.07 Mn |
| Dec 31, 2025 | -3.07 Mn |
| Sep 30, 2025 | -5.32 Mn |
| Sep 30, 2025 | -5.32 Mn |
| Jun 30, 2025 | -459,000.00 |
| Jun 30, 2025 | -459,000.00 |
| Mar 31, 2025 | -4.38 Mn |
| Mar 31, 2025 | -4.38 Mn |
| Dec 31, 2024 | -7.26 Mn |
| Dec 31, 2024 | -7.26 Mn |
| Sep 30, 2024 | -770,000.00 |
| Sep 30, 2024 | -770,000.00 |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | -743,000.00 |
| Mar 31, 2024 | -743,000.00 |